Here, we show that CoREST inhibition in human melanoma cell lines reversed the 2 major melanoma cell phenotypes, those characterized as either MITFhi/AXLlo or MITFlo/AXLhi, and resensitized BRAFi-resistant (BRAFi-R) melanoma cells to BRAFi therapy. Here, RCOR1 is linked to melanoma.